Related Experiment Videos

Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications

Guido Boerrigter1, John C Burnett

  • 1Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Current Heart Failure Reports
|July 23, 2005
PubMed

Insights

Impaired kidney function is a key indicator for patients with congestive heart failure (CHF). New therapies targeting renal function may improve outcomes, but require further study.

Area of Science:

  • Cardiology
  • Nephrology

Background:

  • Impaired renal function is a significant prognostic indicator in congestive heart failure (CHF).
  • Conventional diuretic therapies can worsen renal dysfunction and activate neurohumoral pathways in CHF patients.

Purpose of the Study:

  • To explore novel therapeutic strategies for enhancing renal function in patients with CHF.
  • To review emerging treatments that may mitigate renal dysfunction associated with CHF.

Main Methods:

  • Review of current evidence linking renal function to CHF prognosis.
  • Identification and discussion of new therapeutic approaches targeting renal enhancement in CHF.
  • Emphasis on the need for prospective trials to validate new strategies.

Main Results:

  • Evidence suggests a strong correlation between renal impairment and poor prognosis in CHF.
  • New strategies like B-type natriuretic peptide, adenosine and vasopressin antagonists, and ultrafiltration show potential for renal improvement.
  • Current data highlights the limitations of conventional diuretics in managing CHF-related renal dysfunction.

Conclusions:

  • Novel renal-enhancing therapies offer promising avenues for managing CHF.
  • Further prospective research is essential to ascertain the clinical benefits and impact on patient outcomes of these emerging strategies in CHF.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.